About Sengenics
Sengenics: Revolutionizing the Discovery of Autoantibody Biomarkers
Sengenics is a leading biotechnology company that specializes in developing industry-first seromics technologies. The company's unique capabilities have revolutionized the discovery of clinically relevant autoantibody biomarkers, which are essential for diagnosing and treating various diseases.
With its headquarters in Singapore, Sengenics has established itself as a global leader in the field of seromics. The company's cutting-edge technologies have been used by researchers and clinicians worldwide to identify novel biomarkers for autoimmune diseases, cancer, infectious diseases, and other conditions.
What sets Sengenics apart from other biotech companies is its focus on protein arrays. Unlike traditional methods that rely on DNA or RNA sequencing to identify biomarkers, Sengenics uses protein arrays to detect autoantibodies directly. This approach provides several advantages over conventional methods.
Firstly, protein arrays allow for high-throughput screening of thousands of proteins simultaneously. This means that researchers can quickly identify potential biomarkers without having to test each one individually. Secondly, protein arrays are highly sensitive and specific, which means they can detect even low levels of autoantibodies with high accuracy.
Sengenics' flagship technology is called KREX (Killer-REx), which stands for "Killer-Exonuclease." KREX is a patented platform that enables the production of full-length recombinant proteins with native conformations. This technology allows researchers to screen large numbers of proteins at once while maintaining their natural structure and function.
Another key technology developed by Sengenics is called ImmuSAFE (Immunoglobulin Signature Assessment by Fluorescence Emission). ImmuSAFE is a proprietary method for detecting autoantibodies using fluorescently labeled antigens. This technique allows researchers to visualize the binding patterns between antibodies and antigens in real-time.
Sengenics' technologies have been used in numerous research studies and clinical trials. For example, the company collaborated with researchers at the University of Oxford to identify autoantibody biomarkers for multiple sclerosis (MS). The study, which was published in Nature Communications, identified several novel biomarkers that could be used to diagnose and monitor MS.
Sengenics has also partnered with several pharmaceutical companies to develop new drugs based on its seromics technologies. In 2019, the company announced a collaboration with Takeda Pharmaceutical Company Limited to discover and validate autoantibody biomarkers for inflammatory bowel disease (IBD).
In addition to its research collaborations, Sengenics offers a range of services to support drug discovery and development. These services include protein expression and purification, antibody production, assay development, and bioinformatics analysis.
Overall, Sengenics is a pioneering biotech company that has transformed the field of seromics. Its innovative technologies have enabled researchers worldwide to accelerate the discovery of clinically relevant autoantibody biomarkers for various diseases. With its continued focus on innovation and collaboration, Sengenics is poised to make even greater contributions in the years ahead.